A pharmaceutical acquisition may look like a corporate transaction from the outside. For employees, it can create a series of personal financial decisions that arrive almost simultaneously.

On October 8, 2026, Viatris announced an agreement to acquire Pacira BioSciences for $36.50 per share in cash. The transaction is expected to close by the end of 2026, subject to the tender offer and other customary closing conditions.

According to Pacira’s SEC filing, outstanding RSUs, performance share units and certain cash-based awards will be converted into cash when the merger becomes effective. In-the-money stock options will generally receive the difference between the acquisition price and their exercise price.

That means employees could receive a substantial amount of taxable compensation in a compressed period, whether or not they planned to sell their equity.

The Pacira transaction provides a timely example, but the larger lesson applies throughout the pharmaceutical industry:

When an acquisition changes the treatment of your equity compensation, it can also change your taxes, investments, benefits and retirement timeline.

The transaction agreement determines what happens to your equity

There is no universal rule governing employee equity during an acquisition.

Your awards could be:

  • Converted into cash
  • Replaced with equity in the acquiring company
  • Continued under their existing vesting schedule
  • Accelerated at closing
  • Canceled if certain conditions are not met
  • Divided between an immediate payment and a future retention award

The outcome depends on the merger agreement, your company’s equity plan and the individual award agreement.

Employees should not assume that an unvested award will disappear. They also should not assume that it will continue under its original schedule.

In the Pacira transaction, outstanding RSUs and PSUs are expected to be converted into cash at the acquisition price, including awards that are unvested immediately before the merger becomes effective. The agreement provides different treatment for stock options depending on whether the $36.50 acquisition price exceeds the option’s exercise price.

This illustrates why the first step is identifying exactly what you own and how each award will be treated. For related planning before an employment transition, read What Happens to Unvested RSUs When You Leave a Pharma Employer?

RSUs may become taxable cash sooner than expected

RSUs are generally taxed as wage income when they vest and settle. In a cash acquisition, the merger agreement may cause outstanding awards to be canceled and replaced with cash when the transaction closes.

For employees with significant unvested awards, this can pull income into a year that already includes:

  • Salary
  • Annual bonuses
  • Previously scheduled RSU vesting
  • Performance awards
  • Deferred-compensation distributions
  • Severance or retention payments
  • Income earned by a spouse

The result may be substantially more taxable income than originally projected for the year.

The payment may also occur without the employee making an affirmative decision to sell company stock. The transaction itself creates the liquidity event.

That makes the expected closing date an important tax-planning variable.

Withholding may not cover the final tax liability

When equity compensation is converted into cash, the employer will generally withhold applicable taxes from the payment. However, withholding is only a prepayment toward the employee’s ultimate tax liability.

For 2026, federal withholding on separately identified supplemental wages may be calculated at 22% when the employee’s supplemental wages for the year do not exceed $1 million. A mandatory 37% rate applies to supplemental wages exceeding $1 million.

Neither percentage necessarily equals the employee’s actual marginal tax rate.

A pharmaceutical executive who receives salary, a bonus and a large equity payout could owe federal income tax at a rate higher than the withholding applied to part of the payment. State taxes and the Additional Medicare Tax may also affect the final result.

Before the transaction closes, estimate:

  • The amount expected from each award
  • The portion likely to be treated as wages
  • Federal and state tax withholding
  • Other income expected during the year
  • Whether estimated tax payments may be needed
  • Whether income could affect deductions, credits or other tax-sensitive decisions

A large payment can feel fully taxed because a substantial amount was withheld. The tax return may tell a different story.

This is where a coordinated Lifetime Tax Strategy becomes important. The transaction should be evaluated alongside the household’s other income and financial decisions.

Stock options require separate attention

The treatment of stock options depends on the acquisition agreement, the exercise price and the type of option.

Under the Pacira agreement, an outstanding option with an exercise price below $36.50 is expected to be converted into a cash payment based on the difference between the acquisition price and the exercise price.

An option with an exercise price equal to or greater than $36.50 is expected to be canceled without payment.

For example, an option to purchase 1,000 shares at $20 per share would have a potential transaction value of:

1,000 × ($36.50 − $20.00) = $16,500

An option to purchase shares at $40 would have no value under those terms because the exercise price exceeds the acquisition price.

The tax consequences may differ depending on whether the options are nonqualified stock options or incentive stock options. Do not exercise an option solely because an acquisition was announced without first reviewing the award terms, expiration date, tax treatment and transaction documents.

A forced sale replaces an investment decision with a cash-flow decision

Before an acquisition, an employee may be deciding whether to keep or sell employer stock.

A cash transaction can remove that decision. The employee no longer owns the company stock and instead receives cash.

The next question becomes:

What should the proceeds accomplish?

Potential uses could include:

  • Setting aside additional money for taxes
  • Replenishing emergency reserves
  • Paying down high-interest debt
  • Replacing compensation that may be lost after the acquisition
  • Diversifying into a broader investment portfolio
  • Funding education or another near-term goal
  • Supporting a career transition
  • Advancing an anticipated retirement date

The proceeds should not remain indefinitely in a settlement account simply because no investment plan was in place.

A large cash payment needs a defined role within your financial plan. For additional guidance, explore Investment Management.

Do not overlook deferred compensation and employee benefits

Equity awards usually receive the most attention during an acquisition, but they are only one part of the employee’s financial picture.

You should also review:

  • Nonqualified deferred-compensation elections and distributions
  • Annual and long-term cash incentives
  • Retention or transaction bonuses
  • Severance arrangements
  • Pension benefits
  • 401(k) plan provisions
  • Health insurance and COBRA eligibility
  • Health savings accounts
  • Life and disability insurance
  • Employee stock purchase plan shares
  • Change-in-control provisions
  • Restrictive covenants and employment agreements

Some benefits may continue, some may transfer to the acquiring company and others may terminate.

Deferred-compensation arrangements deserve particular attention because they are generally unsecured obligations of the employer. The plan documents and transaction terms determine whether balances continue, transfer or become payable.

Do not assume every component of your compensation package will follow the treatment of your RSUs.

Consider the effect on your retirement timeline

An acquisition can change more than the value of an equity award.

It may affect:

  • How long you expect to remain employed
  • Whether you qualify for a pension milestone
  • The timing of future bonuses
  • Healthcare coverage before Medicare
  • Your ability to continue saving through the company retirement plan
  • The availability of future equity grants
  • The year in which deferred compensation is paid
  • The amount of cash available to fund retirement

An employee who planned to retire in two years may receive enough cash to consider leaving earlier. Another employee may need to remain through a retention period or benefit milestone.

The acquisition should be modeled as part of the retirement plan, not treated as an isolated windfall.

Six steps to take after an acquisition is announced

  1. Create a complete compensation inventory. List every RSU, PSU, stock option, ESPP share, cash award, deferred-compensation balance and expected bonus. Include the vesting dates, exercise prices and estimated values.
  2. Read the actual transaction and award documents. Company announcements summarize the transaction, but the merger agreement, equity plan and individual award agreements govern the details. Look for acceleration provisions, payment timing, continued vesting requirements and change-in-control language.
  3. Project the tax year. Estimate total household income under different possible closing dates. Compare expected withholding with the projected tax liability. This is especially important if the transaction could close near year-end.
  4. Review benefits and employment milestones. Identify pension dates, retirement-plan contributions, healthcare needs, severance provisions and retention requirements that could influence an employment decision.
  5. Decide what the cash will do. Determine how much should remain liquid, how much should be reserved for taxes and how much can be invested toward longer-term goals.
  6. Revisit the retirement plan. Test whether the transaction changes your retirement date, income strategy or ability to absorb investment risk.

Frequently Asked Questions

Do unvested RSUs disappear when a company is acquired?

Not necessarily. They may be converted into cash, replaced with awards from the acquiring company, accelerated or continued under an existing schedule. The merger agreement and equity-plan documents determine the treatment.

Will a cash payment for my RSUs be taxable?

RSU payments are generally treated as wage income when they vest and settle. The timing and reporting should be confirmed from the transaction documents and subsequent payroll statements.

What happens to stock options that are underwater?

In a cash acquisition, options with an exercise price at or above the acquisition price may be canceled without payment. The specific transaction agreement controls the outcome.

Is the tax withholding taken from the payment enough?

Not always. The withholding rate may be lower than your marginal federal tax rate, particularly when salary, bonuses and equity payments create a high-income year.

Should I invest all the proceeds immediately?

Not before determining how much may be needed for taxes, near-term expenses or a possible employment transition. The remaining amount can then be coordinated with your long-term investment strategy.

Create a plan before the transaction closes

A pharmaceutical acquisition can turn several years of anticipated equity compensation into a single cash payment.

That may create opportunity, but it can also create unexpected taxes, excess cash, benefit changes and pressure to make important decisions quickly.

Start by understanding what the agreement does to each component of your compensation. Then coordinate the proceeds with your taxes, investments, benefits and retirement timeline.

Your employer’s transaction determines how your awards are paid. Your financial plan determines what happens next.

Take the Next Step

If an acquisition, restructuring or employment transition is changing your equity compensation, taxes or retirement timeline, an Integrated Retirement Review can help bring those decisions together.

‍